Logo image of IBIO

IBIO INC (IBIO) Stock Fundamental Analysis

NYSEARCA:IBIO - NYSE Arca - US4510337086 - Common Stock - Currency: USD

3.48  -0.15 (-4.13%)

After market: 3.49 +0.01 (+0.29%)

Fundamental Rating

2

Overall IBIO gets a fundamental rating of 2 out of 10. We evaluated IBIO against 571 industry peers in the Biotechnology industry. IBIO may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, IBIO is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year IBIO has reported negative net income.
In the past year IBIO has reported a negative cash flow from operations.
IBIO had negative earnings in each of the past 5 years.
IBIO had a negative operating cash flow in each of the past 5 years.
IBIO Yearly Net Income VS EBIT VS OCF VS FCFIBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

IBIO has a Return On Assets of -94.42%. This is in the lower half of the industry: IBIO underperforms 73.53% of its industry peers.
IBIO has a worse Return On Equity (-130.39%) than 61.46% of its industry peers.
Industry RankSector Rank
ROA -94.42%
ROE -130.39%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IBIO Yearly ROA, ROE, ROICIBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

IBIO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IBIO Yearly Profit, Operating, Gross MarginsIBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

3

2. Health

2.1 Basic Checks

IBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
There is no outstanding debt for IBIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
IBIO Yearly Shares OutstandingIBIO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 200K 400K 600K 800K
IBIO Yearly Total Debt VS Total AssetsIBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M

2.2 Solvency

Based on the Altman-Z score of -16.80, we must say that IBIO is in the distress zone and has some risk of bankruptcy.
IBIO has a worse Altman-Z score (-16.80) than 84.55% of its industry peers.
A Debt/Equity ratio of 0.04 indicates that IBIO is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.04, IBIO is doing worse than 61.81% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Altman-Z -16.8
ROIC/WACCN/A
WACC9.94%
IBIO Yearly LT Debt VS Equity VS FCFIBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

IBIO has a Current Ratio of 3.37. This indicates that IBIO is financially healthy and has no problem in meeting its short term obligations.
IBIO has a worse Current ratio (3.37) than 60.04% of its industry peers.
A Quick Ratio of 3.37 indicates that IBIO has no problem at all paying its short term obligations.
IBIO has a Quick ratio of 3.37. This is comparable to the rest of the industry: IBIO outperforms 41.92% of its industry peers.
Industry RankSector Rank
Current Ratio 3.37
Quick Ratio 3.37
IBIO Yearly Current Assets VS Current LiabilitesIBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

5

3. Growth

3.1 Past

IBIO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 92.74%, which is quite impressive.
Looking at the last year, IBIO shows a very strong growth in Revenue. The Revenue has grown by 250.00%.
Measured over the past years, IBIO shows a very negative growth in Revenue. The Revenue has been decreasing by -35.53% on average per year.
EPS 1Y (TTM)92.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.35%
Revenue 1Y (TTM)250%
Revenue growth 3Y-54.38%
Revenue growth 5Y-35.53%
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to grow by 14.99% on average over the next years. This is quite good.
The Revenue is expected to grow by 315.61% on average over the next years. This is a very strong growth
EPS Next Y78.54%
EPS Next 2Y34.7%
EPS Next 3Y24.06%
EPS Next 5Y14.99%
Revenue Next Year1100%
Revenue Next 2Y300%
Revenue Next 3Y-25.99%
Revenue Next 5Y315.61%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
IBIO Yearly Revenue VS EstimatesIBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 10M 20M 30M
IBIO Yearly EPS VS EstimatesIBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -100 -200 -300

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IBIO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IBIO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IBIO Price Earnings VS Forward Price EarningsIBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IBIO Per share dataIBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

IBIO's earnings are expected to grow with 24.06% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.7%
EPS Next 3Y24.06%

More info and screens

0

5. Dividend

5.1 Amount

IBIO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IBIO INC

NYSEARCA:IBIO (2/21/2025, 8:27:04 PM)

After market: 3.49 +0.01 (+0.29%)

3.48

-0.15 (-4.13%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-07 2025-02-07
Earnings (Next)05-12 2025-05-12
Inst Owners26.65%
Inst Owner Change-93.94%
Ins Owners7.76%
Ins Owner Change0.54%
Market Cap34.35M
Analysts82.5
Price Target4.96 (42.53%)
Short Float %2.35%
Short Ratio1.07
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-41.47%
Min EPS beat(2)-88.99%
Max EPS beat(2)6.05%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)13.18%
EPS NQ rev (1m)-4.55%
EPS NQ rev (3m)-4.55%
EPS NY rev (1m)10.42%
EPS NY rev (3m)10.42%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 196.27
P/FCF N/A
P/OCF N/A
P/B 1.93
P/tB 2.77
EV/EBITDA N/A
EPS(TTM)-6.63
EYN/A
EPS(NY)-1.4
Fwd EYN/A
FCF(TTM)-1.74
FCFYN/A
OCF(TTM)-1.72
OCFYN/A
SpS0.02
BVpS1.8
TBVpS1.26
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -94.42%
ROE -130.39%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 23.81%
Cap/Sales 120%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.37
Quick Ratio 3.37
Altman-Z -16.8
F-Score5
WACC9.94%
ROIC/WACCN/A
Cap/Depr(3y)334.18%
Cap/Depr(5y)253.6%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)92.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.35%
EPS Next Y78.54%
EPS Next 2Y34.7%
EPS Next 3Y24.06%
EPS Next 5Y14.99%
Revenue 1Y (TTM)250%
Revenue growth 3Y-54.38%
Revenue growth 5Y-35.53%
Sales Q2Q%-100%
Revenue Next Year1100%
Revenue Next 2Y300%
Revenue Next 3Y-25.99%
Revenue Next 5Y315.61%
EBIT growth 1Y21.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y67.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y59.78%
OCF growth 3YN/A
OCF growth 5YN/A